Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Consider renal function in TLS risk assessment of venetoclax-treated CLL

Key clinical point: Impaired renal function appears to be associated with risk of tumor lysis syndrome (TLS) in venetoclax-treated patients.

Major finding: The area under the receiver operating characteristic curve was 74.6% when creatinine clearance was added to the standard model for assessing TLS risk, compared with 65% for the standard approach.

Study details: A retrospective cohort study of 339 CLL patients.

Disclosures: Dr. Mato has received grant support, consulting fees, and/or fees for serving on a data and safety monitoring board or advisory board from AbbVie, AstraZeneca, Celgene, Janssen, TG Therapeutics, Pharmacyclics, Loxo, Sunesis, prIME Oncology, Pfizer, Johnson & Johnson, and Regeneron.

Citation:

Mato A et al. iwCLL 2019, Abstract 2008.